BacDrug SIGNED
Bacterial membrane vesicles a novel delivery system for the treatment of multi-drug resistant Gram-negative bacterial infections.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0BacDrug project word cloud
Explore the words cloud of the BacDrug project. It provides you a very rough idea of what is the project "BacDrug" about.
Project "BacDrug" data sheet
The following table provides information about the project.
| Coordinator |
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 212˙933 € |
| EC max contribution | 212˙933 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2018 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-01-01 to 2021-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE | UK (LONDON) | coordinator | 212˙933.00 |
Map
Project objective
'Bacterial infections are a significant public health challenge and a major cause of human mortality globally. Antibiotics are indispensable for the treatment and prevention of infections caused by bacteria. However, global spread of drug-resistant bacteria, coupled with a dearth of new antibiotics in development has led to an alarming shortage of effective drugs. Gram-negative bacteria, in particular, protect themselves against antibiotics with a highly selective outer membrane. The high burden of diseases caused by Gram-negative bacteria, combined with their frequent multi-drug resistance has placed them as world´s highest-priority pathogens by the World Health Organization. Consequently, there is an urgent need for novel therapeutic approaches that combat Gram-negative bacterial pathogens. The goal of 'BacDrug' is to use lipid-based bacterial membrane vesicles (BMVs) produced by non-pathogenic Lactococcus lactis as delivery system. BMVs have great potential as nanocarriers to by-pass the outer membrane and deliver their toxic payload to kill drug-resistant Gram-negative pathogens. A range of strategies will be used to load BMVs with cargo, including genetic engineering of L. lactis as well as chemical treatments. This Fellowship will harness expertise and techniques across microbiology, molecular biology, nanotechnology and drug design to deliver a successful outcome. The collaborative, truly interdisciplinary, cross faculty setting within the groups of Prof Molly Stevens (materials and bioengineering) and Dr Andrew Edwards (molecular microbiology) at ICL combines world-class expertise and provides an environment to maximise the success of this Fellowship, both in terms of the delivering the project and the training opportunities provided. Moreover, this innovative, alternative strategy to tackle drug-resistant Gram-negative bacterial infections has a high translational potential, which will be exploited via the clinical and translational research clinics at ICL.'
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BACDRUG" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BACDRUG" are provided by the European Opendata Portal: CORDIS opendata.